REISSUED FOR PUBLICATION
NOV 30 2018
OSM
U.S. COURT OF FEDERAL CLAIMS
1fn tbc Wnitcb $fates Qtoutt of jfcbctal Qtlaints
OFFICE OF SPECIAL MASTERS
No.17-0786V
(not to be published)
*************************
V ALISHA CARRINGTON, * Special Master Corcoran
*
* Filed: October 18, 2018
Petitioner, *
V. *
* Dismissal of Petition; Vaccine
SECRETARY OF HEALTH * Act; Denial Without Hearing; Failure
AND HUMAN SERVICES, * to Prosecute.
*
Respondent. *
*
*************************
Valisha Carrington, prose, Round Rock, TX.
Christine M Becer, U.S. Dep't of Justice, Washington, D.C. for Respondent.
DECISION DISMISSING CASE FOR INSUFFICIENT PROOF AND FAILURE TO
PROSECUTE 1
On June 13, 2017, Valisha Carrington filed a petition seeking compensation under the
National Vaccine Injury Compensation Program.2 In it, Ms. Carrington alleged that she suffered
from Guillain-Barre syndrome ("OBS"), acute inflammatory demyelinating polyneuropathy
("AIDP"), and/or chronic inflammatory demyelinating polyneuropathy ("CIDP"), as a result of
receiving the Flumist form of the influenza vaccine on February 23, 2016. See Petition ("Pet.")
(ECF No. 1) at 1-2; Supplemental Petition ("Supp. Pet.") (ECF No. 8-1) at 1-2.
1
Although this Decision has been formally designated "not to be published," it will nevertheless be posted on the
Court ofFederal Claims's website in accordance with the E-Government Act of 2002, 44 U.S.C. § 3501 (2012)). This
means that the Decision will be available to anyone with access to the internet. As provided by 42 U .S.C. § 300aa-
12( d)(4)(8), however, the parties may object to the Decision's inclusion of certain kinds of confidential information.
Specifically, under Vaccine Rule l 8(b ), each party has fourteen days within which to request redaction "of any
information furnished by that party: (l) that is a trade secret or commercial or financial in substance and is privileged
or confidential; or (2) that includes medical files or similar files, the disclosure of which would constitute a clearly
unwan-anted invasion of privacy." Vaccine Rule 18(b). Otherwise, the whole Decision will be available to the public.
Id.
2 The Vaccine Program comprises Part 2 of the National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660,
100 Stat. 3758, codified as amended at 42 U.S.C. §§ 300aa-10 through 34 (2012) ("Vaccine Act" or "the Act").
Individual section references hereafter will be to § 300aa of the Act (but will omit that statutory prefix).
Following the filing of the Petition, the case proceeded in an overall efficient matter.
Petitioner's prior counsel filed the majority of Petitioner's medical records by June 15, 2017, and
the parties filed the Joint Statement of Completion that same day (though it was later determined
that Respondent required additional records to assess the claim). See ECF Nos. 10, 14. Respondent
thereafter filed his Rule 4(c) Repmt on January 5, 2018, contesting Petitioner's right to an
entitlement award (ECF No. 15). 3
On January 18, 2018, I held an initial status conference to discuss my views of the case in
light of the issues raised in the Rule 4( c) Report. As noted above, the Petition alleged that Ms.
Carrington suffered from OBS, AIDP, and/or CIDP as a result of receiving the Flumist vaccine.
However, Respondent's Rule 4(c) Report highlighted some inconsistencies in the medical records
relating to the evidentiary suppmt for such an injury. See Scheduling Order, dated Jan. 19, 2018
(ECF No. 17). Based on my own assessment of the record, I explained to Petitioner that CIDP
appeared to be the better supported diagnosis, though I allowed for the possibility that an expe1t
opinion could shed more light on the diagnosis dispute. Id. at I. Neve1theless, at the conclusion of
the conference I expressed concern relating to the claim's overall viability (given the questions
about diagnosis, Petitioner's preexisting health problems, and the possibility of conversion
disorder as an alternate explanation for her symptoms). Id. at 1-2. I thus encouraged Petitioner to
be mindful of the above if she intended to proceed with obtaining an expe1t opinion to support her
claim. Id. at I. I thereafter directed Petitioner to file a status report on or before March 23, 2018,
indicating how she wished to proceed moving forward. Id. at 2.
On April 4, 2018, I held an additional status conference with the pmties given Petitioner's
desire to proceed to the expert stage. During the conference, Petitioner's prior counsel informed
me that he had retained Dr. Marcel Kinsbourne in hopes that he could offer an expert opinion in
the matter. See Scheduling Order, dated Apr. 4, 2018 (ECF No. 20) ("April 4th Order"). According
to counsel, Dr. Kinsbourne believed Petitioner had been misdiagnosed, and wanted to evaluate
other possible explanations for her symptoms (including narcolepsy, conversion disorder, or small
fiber neuropathy), none of which were alleged in the Petition (nor supported strongly by the filed
medical records for that matter).
In response, I reiterated my view that the claim likely faced viability problems given the
lack of record support for the new diagnoses offered. April 4 th Order at 1-2. Program precedent
strongly favors the contemporaneous medical records when assessing possible diagnoses (as
opposed to subsequent opinions contradicting earlier-in-time records). Id. Otherwise, given the
lack of Program suppmt for a vaccine-induced injury resulting in narcolepsy, I cautioned Petitioner
that only her newly-alleged small fiber neuropathy diagnosis might be viable (though it too
appeared unsupported by the medical record at that time). Id. at 2.
3 An additional set of neurology records were filed on January 16, 2018. See ECF No. 16.
2
At the conclusion of the April 4th conference, I set a deadline of June 22, 2018, for
Petitioner to file an expert rep01i in supp01i of her claim. See Scheduling Order, dated Apr. 4, 2018
(ECF No. 20). Thereafter, prior counsel filed a status report on June 20, 2018, indicating that
Petitioner had been unable to secure medical expert support for any of the alternative diagnoses
offered in the April 4th conference. See Status Report, filed June 20, 2018 (ECF No. 21). Counsel
neve1iheless requested that Petitioner be given even more time to visit her neurologist or other
specialist (in order to try to obtain one of the aforementioned diagnoses). Id. at 2. He also indicated
a desire to withdraw should I deny any fmiher extensions of time, and requested a status conference
to discuss the matter further. Id.
I held a final status conference on July 12, 2018. During that conference, I again reiterated
to Petitioner my concerns regarding the claim's reasonable basis (given counsel's inability to
obtain an expe1i who could offer a supportive opinion regarding the injuries alleged in the Petition,
as well as Petitioner's unsuccessful attempts to procure an alternative diagnosis over one year after
the case's filing). See Scheduling Order, dated July 12, 2018 (ECF No. 22). In light of the above,
I set a deadline of September 14, 2018, for Petitioner to show cause why her claim should not be
dismissed for failure to offer a cognizable medical theory, supported by the medical record, in
supp01i of a vaccine-induced injury. Id. at 2. I similarly directed former counsel to file a motion to
withdraw and a fees application on or before July 31, 2018. Id.
Prior counsel filed his motion to withdraw and fees application on July 13, 2018, and July
16, 2018, respectively (ECF Nos. 23-26). I granted counsel's motion to withdraw on August 6,
2018 (ECF No. 29). 4 Thereafter, Petitioner entirely missed her show cause deadline set for
September 14, 2018. Thus, on September 21, 2018, I ordered Petitioner to file the overdue response
immediately. See Order, dated Sept. 21, 2018 (ECF No. 34). After Petitioner ignored that deadline
as well, I directed her to again show cause immediately why the case should not be dismissed for
failure to comply with my orders. See Order to Show Cause, dated Oct. 1, 2018 (ECF No. 35).
Despite this Order, Petitioner still has not filed a brief in supp01i of her claim, nor filed a response
of any kind to my Show Cause Order.
Analysis
To receive compensation under the Vaccine Program, a petitioner must prove either (1)
that he suffered a "Table Injury" - i.e., an injury falling within the Vaccine Injury Table -
corresponding to one of her vaccinations, or (2) that he suffered an injury that was actually caused
by a vaccine. See Sections 13(a)(l)(A) and l l(c)(l). An examination of the record, however, does
not uncover preponderant evidence that Petitioner suffered a Table injury. Accordingly, Petitioner
seeks to establish entitlement via a causation-in-fact, non-Table claim - meaning she must meet
the test for such a claim set f01ih by the Federal Circuit in A/then v. Sec '.Y of Health & Human
4 The fees request remains pending. See ECF Nos. 23, 25.
3
Servs., 418 F.3d 1274 (Fed. Cir. 2005). Petitioner has had several chances to offer evidence that
would suppmt her claim, but she has failed to submit such evidence into the record. Overall, the
record does not contain persuasive evidence indicating that Petitioner's alleged injury was vaccine-
caused.
As noted above, Petitioner initially alleged that the Flumist form of the flu vaccine caused
her to develop some form of peripheral neuropathy (i.e. GBS/CIDP/AIDP). Pet. at 1. As the case
progressed, Petitioner contended (in the face of a record that only partially supported a CIDP
diagnosis) that she was likely misdiagnosed, and offered new explanations (including narcolepsy
or small fiber neuropathy), for her purported vaccine-caused injury.
Based on my review of Petitioner's submissions, it appears that the record does contain
some uncertainty concerning her proper diagnosis following vaccine administration. Various
treatment records around the time of vaccination suggest that Petitioner presented to treaters with
complaints (including paresthesia, numbness, and weakness) near the end of March 2016.
However, those same treaters concluded that the relevant medical testing could not explain her
adverse symptoms. See, e.g., Ex. 3 at 44-45 (March 28, 2016 hospitalization record noting
preexisting concern/diagnosis of narcolepsy), 53 (March 28, 2016 neurology consult noting that
GBS/AIDP should be considered, though reflexes were normal and intact), 46-49 (April 1, 2016
psychiatric consult noting GBS would be atypical as Petitioner had retained reflexes), 81-82 (April
1, 2016 neurology consult noting Petitioner's case was odd/atypical for AIDP due to normal MRI
and CSF analysis). Subsequent treaters reached similar conclusions. See, e.g., Ex. 5 at 52, 55
(January 3, 2017 hospital record noting March 2016 GBS/MS workup was unremarkable, resulted
in normal MRI and lumbar puncture, and overall etiology was "not clear"), 68 (January 3, 2017
neurology consult listing CIDP as a differential, but noting presentation would be atypical given
intact reflexes), 90 (January 11, 2017 neurology consult indicating suspected CIDP due to EBV
infection, but noting reflexes were intact and concern for "embellished" symptoms); Ex. 7 at 3-4
(January 26, 2017 neurology consult noting Petitioner "does not have" GBS/CIDP).
Thus, it is clear that Petitioner's treaters never firmly concluded (after much testing) that
her symptoms were compatible with a neuropathic injury (whether GBS, CIDP, or small fiber
neuropathy). On the present record (and absent a medical expert opinion), Petitioner is not able to
establish that she suffered a neuropathic injury following vaccination.
The medical record also includes some support for a diagnosis of narcolepsy. See, e.g., Ex.
2 at 6-7 (March 21, 2016 notation for narcolepsy with cataplexy given breathing troubles and
increased sleepiness upon exam); Ex. 3 at 44-45 (March 28, 2016 hospital record indicating past
diagnosis and sleep study for narcolepsy). However, no treaters ultimately so diagnosed Petitioner.
And Ms. Carrington was unable to obtain a newer narcolepsy diagnosis from some other expe1t -
4
an effoti which (given its undertaking over six months after the claim's filing) smacks more of
desperation to save the claim than a reasonable inquiry into the nature of her alleged injuries. 5
But even if narcolepsy were an alternative credible diagnosis, the contemporaneous
medical records filed in the case do not suppmi the contention that Petitioner's receipt of the
Flumist vaccine caused it. At best, records from Petitioner's March 2016 hospitalization include a
glancing reference to receipt of the Flumist vaccine in her health history. See, e.g., Ex. 3 at 53.
Roughly nine months following vaccine administration, notes in the health history from a January
20 I 7 record state that Petitioner's current allergy list included the "influenza vaccine." See Ex. 5
at 62 (January 2, 2017 hospitalization record concerning visit for extremity weakness); Ex. 7 at 2.
Admittedly, the health history taken during that visit (referring to her previous symptoms in March
2016) notes that "the initial insult was felt to be a flu vaccine." Ex. 5 at 62. However, it appears
more likely that Petitioner reported this histmy to the treating physician (as that same record offers
no explanation or opinion regarding any correlation between the vaccination and any symptoms
she was experiencing at that time or in March 2016). See id. Thus, at best, the records suggest that
Petitioner reported concerns for a vaccine-induced injury--not that treaters offered the view
causally connecting vaccination with any subsequent symptoms she experienced. See, e.g., Ex. 3
at 45 (March 28, 2016 consult noting patient attributed weakness to flu vaccine); 46 (March 28,
2016 consult noting patient reported concern for allergy to Flumist), 50 (noting the same); Ex. 2
at 6 (March 21, 2016, visit noting patient attributed breathing problems and sleepiness to Flumist). 6
Moreover, and independent of the above substantive and objective deficiencies,
Petitioner's claim should also be dismissed due to her repeated failures to comply with my orders.
A petitioner's inaction and failure to abide by court orders risks dismissal of a claim. Tsekouras v.
Sec'y of Health & Human Servs., 26 Cl. Ct. 439 (1992), aff'd per curiam, 991 F.2d 810 (Fed. Cir.
1993); Sapharas v. Sec'y of Health & Human Servs., 35 Fed. Cl. 503 (1996); Vaccine Rule 2l(b).
Petitioner ignored a deadline set by an Order I issued, and then ignored a second warning that the
case would soon be dismissed if she again failed to respond. In each instance I provided her with
5 The record more strongly supports the conclusion that Ms. Canington's symptoms are attributable to conversion
disorder. See Ex. 3 at 46-49 (March 31, 2016 psychiatry consult noting concern for psychological component related
to weakness presentation), 81 (April I, 2016 psychiatric consult noting suspected conversion disorder is "strong
possibility"); Ex. 4 at 23 (April 6, 2016 psychiatric note concluding Petitioner had generalized anxiety disorder); 5 at
68 (January 2, 2017 neurology consult again indicating possible psychological component to symptoms). Of course,
if this is true, then Petitioner's claims that the Flumist vaccine harmed her are even more baseless. See, e.g., Pless v.
Sec'y of Health & Human Servs., No. 16-271, 2017 WL 4174077, at* 5 (Fed. Cl. Spec. Mstr. Aug. 25, 2017)
(conditions without a physical basis, such as somatoform or conversion disorder, are not compensable under the
Vaccine Act) (citing Lasnetski v. Sec), of Health & Human Servs., 696 F. App'x 497 (Fed. Cir. 2017)), aff'd, slip op.
No. 16-271V (Fed. Cl. Jan. 4, 2018)).
6 1 have also previously determined that the Flumist vaccine (as compared with other formulations) cannot be reliably
deemed causal ofnarcolepsy. See D'Toile v. Sec'y of Health & Human Servs., No. 15-085V, 2016 WL 7664475 (Fed.
Cl. Spec. Mstr. Nov. 28, 2016) (denying compensation for Flumist/narcolepsy injury due in pat1 to insufficiencies in
the medical literature filed in support), mot.for review den'd, 132 Fed. Cl. 421 (2017), aff'd, 726 F. App'x 809 (Fed.
Cir. 2018).
5
more than enough time to contact my chambers or file some kind of status report. She was therefore
on ample notice of the risks she took not talcing my orders seriously.
Under the Vaccine Act, a petitioner may not receive a Vaccine Program award based solely
on his claims alone. Rather, the petition must be supported by either medical records or by the
opinion of a competent physician. Section 13(a)(l). In this case, there is insufficient evidence in
the record for Petitioner to meet her burden of proof. Petitioner's claim therefore cannot succeed
and must be dismissed. Section 11 (c)(I )(A).
Thus, this case is dismissed for insufficient proof and failnre to prosecute. The Clerk
shall enter jndgment accordingly.7
IT IS SO ORDERED.
Special Master
7 Pursuant to Vaccine Rule I !(a), the parties may expedite judgment by filing a joint notice renouncing their right to
seek review.
6